Calreticulin and myeloproliferative neoplasms: linking biology to targeted therapies.
Emerging immunotherapy strategies targeting CALR mutations offer a path toward modifying myeloproliferative cancer biology rather than managing symptoms alone.
This review synthesizes the biology of CALR mutations in BCR:ABL1-negative MPNs, detailing constitutive thrombopoietin receptor activation and immunogenic neoepitope generation as rational therapeutic targets. Emerging strategies including INCA033989 monoclonal antibody, peptide vaccines, T-cell engagers, and CAR-T cells offer a path toward disease modification rather than symptom control alone.
What the study was
- Study design
- Narrative review
- Population
- BCR:ABL1-negative myeloproliferative neoplasm (MPN) patients with CALR mutations
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Expert Rev Clin Immunol
Why it surfaced
CALR-targeted therapies for MPN represent a paradigm shift toward clonal elimination; INCA033989 in active clinical evaluation makes this immediately pipeline-relevant for precision MPN therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.